CLVS - Clovis Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5590.64M
Enterprise Value 3779.92M
Trailing P/E N/A
Forward P/E 1-2.08
PEG Ratio (5 yr expected) 1-0.04
Price/Sales (ttm)5.37
Price/Book (mrq)7.68
Enterprise Value/Revenue 37.09
Enterprise Value/EBITDA 6-2.26

Trading Information

Stock Price History

Beta (3Y Monthly) 1.80
52-Week Change 3-76.70%
S&P500 52-Week Change 36.04%
52 Week High 348.21
52 Week Low 310.63
50-Day Moving Average 313.84
200-Day Moving Average 320.70

Share Statistics

Avg Vol (3 month) 31.72M
Avg Vol (10 day) 32.15M
Shares Outstanding 553M
Float 39.23M
% Held by Insiders 13.00%
% Held by Institutions 1103.65%
Shares Short (Jun 28, 2019) 410.42M
Short Ratio (Jun 28, 2019) 45.64
Short % of Float (Jun 28, 2019) 420.55%
Short % of Shares Outstanding (Jun 28, 2019) 419.67%
Shares Short (prior month May 31, 2019) 48.49M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-318.54%

Management Effectiveness

Return on Assets (ttm)-29.92%
Return on Equity (ttm)-197.72%

Income Statement

Revenue (ttm)109.98M
Revenue Per Share (ttm)2.09
Quarterly Revenue Growth (yoy)78.80%
Gross Profit (ttm)75.94M
EBITDA -344.6M
Net Income Avi to Common (ttm)-376.74M
Diluted EPS (ttm)-7.16
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)406.78M
Total Cash Per Share (mrq)7.67
Total Debt (mrq)606.3M
Total Debt/Equity (mrq)810.01
Current Ratio (mrq)4.39
Book Value Per Share (mrq)1.41

Cash Flow Statement

Operating Cash Flow (ttm)-363.81M
Levered Free Cash Flow (ttm)-195.81M